https://www.selleckchem.com/pr....oducts/Vorinostat-sa
PSEN1-H163Y carriers, at the presymptomatic stage, have reduced FDG-PET binding in the cerebrum of the brain (Scholl et al., Neurobiol Aging 321388-1399, 2011). This could imply dysfunctional energy metabolism in the brain. In this study, plasma of presymptomatic PSEN1 mutation carriers was analyzed to understand associated metabolic changes. We analyzed plasma from noncarriers (NC, n=8) and presymptomatic PSEN1-H163Y mutation carriers (MC, n=6) via untargeted metabolomics using gas and liquid chromatography coupled with mass sp
Like
Comment
Share
